Fullness is not muscle
Three compounds, three different stories, and one measurement problem that explains all of them. The scan moves. The muscle does not.
The community named food noise
The most consistent report in a million GLP-1 threads was never coined in a trial. How a community phrase crossed into the peer-reviewed literature, what users actually mean by it, and the one thing it still cannot prove.
BPC-157 will never be tested
A phase 3 programme is repaid by exclusivity and BPC-157's sequence has been public since 1993. Nobody will ever fund the trial — a market design, not a verdict, and not a conspiracy. Introduces the trial-blocked flag.
Banned in sport, untested
Sport names these compounds, funds the chemistry to catch them, and suspended 34 players in one case. Medicine has run almost no trials. That asymmetry is real evidence — of something other than efficacy.
What anecdote can prove
The largest uncontrolled experiment in modern self-medication, read seriously — five tiers of community evidence ranked by what each can actually establish, and the placebo mechanics that decide it.
Peptides in 2026, graded
Seventeen compounds, one ladder, no generosity. Two hold an FDA approval for what they are sold to do, seven grade D, and the thing everyone called a legalisation in April 2026 was the opposite.
GHK-Cu, route by route
Three randomised trials in forty years, two of them negative, and not one measurement of elastin in a living human. Topical GHK-Cu grades D. Sunscreen grades A.
Forty skin interventions, ranked
Sunscreen and tretinoin hold the only multi-year randomised evidence. Two retractions, one negative copper-peptide trial nobody cites, and zero injectable peptides with a skin endpoint. The whole field on one A–E ladder.
Vendors graded on paper
We graded vendors on one axis only: the quality documents they actually publish. Named labs, real accession numbers, measured fill — or nothing.
Read the certificate
Purity is one number. Identity, net content, endotoxin, and microbial screening are the ones most certificates quietly skip. The five-measure checklist, step by step.
Where the powder comes from
Nearly every vial on the US market starts as bulk API from a small set of overseas synthesizers. FDA's Import Alert 66-80 now detains GLP-1 shipments by default — unless the maker is one of 19 green-listed firms worldwide. Here is how to check a supplier yourself.
Retatrutide: best data, unproven
The phase 2 numbers everyone quotes, what the phase 3 program still has to prove, and where the hype outruns the data.
How much muscle you lose
Roughly a quarter to a third of the weight lost on GLP-1 agonists can be lean mass. The trial data, the resistance-training counterweight, and the protein math.
Why your card gets declined
Peptide vendors live outside the mainstream payment rails. What that means for you — and what a crypto-only checkout is telling you.
The GLP-1 turf war
Shortage rules built the compounded GLP-1 market and shortage rules are unwinding it. Where telehealth, 503A pharmacies, and research-use vendors actually stand right now.
BPC-157: The Evidence, Graded Honestly
The most-searched healing peptide on the market rests almost entirely on animal data. What the studies show, what they don't, and why WADA bans it anyway.
"Tested" is not one thing
USP <71> sterility, USP <85> endotoxin, and PCR microbial screens are three different tests. Most vendors run one of them at most — and the word "tested" hides the difference.